# First-Line Nivolumab Plus Ipilimumab in Unresectable Hepatocellular Carcinoma (J-PROMISE)

> **NCT07679061** · — · RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 200 (estimated)

## Conditions studied

- Unresectable Hepatocellular Carcinoma

## Interventions

- **COMBINATION_PRODUCT:** Nivolumab plus ipilimumab

## Key facts

- **NCT ID:** NCT07679061
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-05
- **Primary completion:** 2028-02-29
- **Final completion:** 2028-02-29
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-07-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07679061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07679061, "First-Line Nivolumab Plus Ipilimumab in Unresectable Hepatocellular Carcinoma (J-PROMISE)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07679061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*